Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today reported that it holds approximately $75 million in cash with no debt, following the completion of its recently announced financing led by dedicated healthcare-focused institutional investors.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.